Abstract: Provided herein are therapeutic methods, kits, and pharmaceutical compositions for protecting a subject from radiation using a therapeutic agent selected from the group consisting of RRx-001 and a pharmaceutically acceptable salt thereof. One exemplary therapeutic method involves administering RRx-001 to the subject prior to the subject being exposed to the radiation, in order to protect the subject against radiation, such as ionizing radiation containing ?-rays, ?-rays, ?-rays, neutron radiation, or a combination thereof.

Abstract: Provided herein are therapeutic methods, kits, and pharmaceutical compositions for protecting a subject from radiation using a therapeutic agent selected from the group consisting of RRx-OO1 and a pharmaceutically acceptable salt thereof. One exemplary therapeutic method involves administering RRx-OO1 to the subject prior to the subject being exposed to the radiation, in order to protect the subject against radiation, such as ionizing radiation containing ?-rays, ?-rays, ?-rays, neutron radiation, or a combination thereof.

Abstract: The invention provides compositions and methods for administering a therapeutic agent to a patient, such as pharmaceutical compositions containing a blood product and a therapeutic agent selected from an anthracycline anti-cancer agent (e.g., doxorubicin), a topoisomerase inhibitor, an oxazaphosphinanyl anti-cancer agent, a nitro-aryl anti-cancer agent, a thiol-reactive functional group agent, a nitric oxide modulator, a platinum-based antineoplastic compound, acrylamide, acrylonitrile, bis(4-fluorobenzyl)trisulfide, a cardiac glycoside, an anti-mitotic agent (e.g., paclitaxel), a nucleoside analog, an EGFR inhibitor, or an anti-microbial agent.

Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., an IL-10 trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion protein, or an expression vector encoding for the fusion proteins, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

Abstract: The invention relates to a recombinant adenovirus that expresses endostatin, angiostatin, or a combination of endostatin and angiostatin. The invention also relates to method of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a combination of (i) a recombinant adenovirus and (ii) an anti-angiogenic agent to treat the cancer in the subject.

Abstract: The invention provides sulfoxyalkyl organonitro and related compounds, compositions containing such compounds, and methods for using such compounds and compositions to treat medical disorders, such as a neurodegenerative disorder, autoimmune disease, infection, or cancer in a patient. Exemplary sulfoxyalkyl organonitro compounds described herein include ((2-(3,3-dinitroaze-tidin-1-yl)-2-oxoethyl)sulfinyl)-D-alanine and variants thereof.

Abstract: The invention relates to a recombinant adenovirus comprising two or more therapeutic transgenes, e.g., two components of a heterodimeric cytokine, separated by a cleavable linker.

Abstract: The invention relates to a method for producing a recombinant virus, e.g., a recombinant oncolytic adenovirus, using an A549 host cell.

Abstract: The invention provides therapeutic methods and kits for treating a glioma using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and one of temozolomide, irinotecan, or bevacizumab.

Abstract: The invention provides methods, compositions, and medical kits comprising a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders and preservation of blood products. In one aspect, the invention provides methods, compositions, and medical kits comprising an inorganic nitrite salt and a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders, such as cancer, cardiovascular disorders, ischemic conditions, hemolytic conditions, and bacterial infections. Exemplary inorganic nitrite salts include sodium nitrite and arginine nitrite. Exemplary allosteric modulators of hemoglobin described herein include alkyl-substituted and acyl-substituted di-nitroheterocycles.

Abstract: The invention provides a recombinant adenovirus comprising two (or more) therapeutic transgenes, e.g., CD80 and CD137L. The transgenes are preferably inserted into an E1b-19K insertion site and/or an E3 insertion site.

Abstract: The invention provides, e.g., a recombinant virus comprising (i) a modified TATA box-based promoter, and/or (ii) a modified CAAT box-based promoter operably linked to a gene, wherein the modified TATA box-based promoter and/or modified CAAT box-based promoter lacks a functional TATA box and/or CAAT box and permit selective expression of the gene in a hyperproliferative cell. The recombinant viruses can be used to treat cell proliferative diseases and disorders, including certain forms of cancer.

Abstract: The invention provides compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone (ABDNAZ), including formulations containing autologous whole blood and ABDNAZ that can be rapidly administered to a patient by intravenous infusion without any significant pain at the site of infusion.

Abstract: The invention provides therapeutic methods and kits for treating brain metastases using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and optionally an additional anti-cancer agent.

Abstract: The invention provides therapeutic methods and kits for treating a glioma using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and one of temozolomide, irinotecan, or bevacizumab.

Abstract: The invention provides therapeutic methods and kits for treating a glioma using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and one of temozolomide, irinotecan, or bevacizumab.

Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., a TGF? trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion proteins, or expression vectors encoding for the fusion proteins, e.g., oncolytic adenoviral expression vectors, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

Abstract: Topical compositions having as the active ingredient a lipid, fatty acid ester, natural wax, sterol, or combinations thereof referred to herein as “lipophilic vehicle” or “LV” and methods of use, have been developed for the amelioration or prevention of pain or the sequelae of pain. The composition may be in the form of an ointment, cream, gel, lotion, spray, foam, paste, patch, suspension or dispersion. The composition is variably effective to treat visceral, somatic and neuropathic pain both acute and chronic as well as muscle pain and stiffness and joint pain and stiffness.

Abstract: Provided are methods and compositions for treating and preventing hyperproliferative disorders such as psoriasis by administration of a cardiac glycoside alone or in combination locally or systemically with a calciotropic agents and/or a diffusion-limiting component, such a vasoconstrictor or collagen barrier.

Abstract: The invention provides organonitro thioether compounds, compositions containing such compounds, isolated organonitro thioether compounds and methods for using such compounds and compositions to treat cancer in a patient. Exemplary organonitro thioether compounds described herein include 2-(3,3-dinitroazetidin-1-yl)-2-oxoethyl thioethers and variants thereof.